overview of the use and adoption of brain SRS in the modern era of RT for brain metastases, serves as a foundation for further research into drivers of uptake and disparities, and highlights the need for prospective comparative effectiveness research in
Search Results
Benjamin H. Kann, Henry S. Park, Skyler B. Johnson, Veronica L. Chiang, and James B. Yu
Julia R. Trosman, Christine B. Weldon, Michael P. Douglas, Allison W. Kurian, R. Kate Kelley, Patricia A. Deverka, and Kathryn A. Phillips
. Trosman JR Weldon CB Schink JC . What do providers, payers and patients need from comparative effectiveness research on diagnostics? The case of HER2/neu testing in breast cancer . J Comp Eff Res 2013 ; 2 : 461 – 477 . 34. Trosman JR Weldon
Ashley E. Rosko, Sarah Wall, Robert Baiocchi, Don M. Benson, Jonathan E. Brammer, John C. Byrd, Yvonne A. Efebera, Kami Maddocks, Kerry A. Rogers, Desiree Jones, Lara Sucheston-Campbell, Hancong Tang, Hatice Gulcin Ozer, Ying Huang, Christin E. Burd, and Michelle J. Naughton
. Basch E , Abernethy AP , Mullins CD , Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology . J Clin Oncol 2012 ; 30 : 4249 – 4255 . 10.1200/JCO.2012.42.5967 23071244
James L. Mohler, Andrew J. Armstrong, Robert R. Bahnson, Anthony Victor D'Amico, Brian J. Davis, James A. Eastham, Charles A. Enke, Thomas A. Farrington, Celestia S. Higano, Eric M. Horwitz, Michael Hurwitz, Christopher J. Kane, Mark H. Kawachi, Michael Kuettel, Richard J. Lee, Joshua J. Meeks, David F. Penson, Elizabeth R. Plimack, Julio M. Pow-Sang, David Raben, Sylvia Richey, Mack Roach III, Stan Rosenfeld, Edward Schaeffer, Ted A. Skolarus, Eric J. Small, Guru Sonpavde, Sandy Srinivas, Seth A. Strope, Jonathan Tward, Dorothy A. Shead, and Deborah A. Freedman-Cass
panel believes that men with clinically localized disease may consider the use of tumor-based molecular assays at this time. Future comparative effectiveness research may allow these tests and others like them to gain additional evidence regarding their
James L. Mohler, Emmanuel S. Antonarakis, Andrew J. Armstrong, Anthony V. D’Amico, Brian J. Davis, Tanya Dorff, James A. Eastham, Charles A. Enke, Thomas A. Farrington, Celestia S. Higano, Eric Mark Horwitz, Michael Hurwitz, Joseph E. Ippolito, Christopher J. Kane, Michael R. Kuettel, Joshua M. Lang, Jesse McKenney, George Netto, David F. Penson, Elizabeth R. Plimack, Julio M. Pow-Sang, Thomas J. Pugh, Sylvia Richey, Mack Roach III, Stan Rosenfeld, Edward Schaeffer, Ahmad Shabsigh, Eric J. Small, Daniel E. Spratt, Sandy Srinivas, Jonathan Tward, Dorothy A. Shead, and Deborah A. Freedman-Cass
persistence or recurrence (category 2B). Future comparative effectiveness research may allow these tests and others like them to gain additional evidence regarding their utility for better risk stratification of men with prostate cancer. Table 1. Available
